Skip to main content
OpenTrials
Completed

NCT Number: NCT00645151

A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol

The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Pfizer Investigational Site, Belo Horizonte, Minas Gerais, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with high cholesterol eligible for treatment with baseline LDL-C level of less than or equal to 220 mg/dL
  • Willingness to follow diet

Exclusion criteria

  • Triglycerides less than or equal to 400 mg/dL
  • Hemoglobin A1c >10%

Treatment and study plan

atorvastatin

Drug

Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.

Primary outcomes

  1. Responder rate in patients who achieved low-density lipoprotein cholesterol (LDL-C) level

    Time frame: Week 8

Secondary outcomes

  1. Percentage of patients achieving LDL goal at 2 and 4 weeks

    Time frame: Weeks 2 and 4

  2. Lipid changes at week 4 & 8

    Time frame: Weeks 4 and 8

Sponsors and collaborators

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Industry

Registry information

Official study title

A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study)

Acronym: LA ATGOAL

Important dates

Study start
2004
Study completion
2005
First posted
Mar 27, 2008
Registry last updated
Feb 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.